Oncorus, Inc. (ONCR)
|Net Income (ttm)||-43.35M|
|Trading Day||January 22|
|Day's Range||25.60 - 26.76|
|52-Week Range||15.00 - 35.55|
Oncorus Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177
-- Preclinical findings show that ONCR-177's systemic antitumor immunity is driven by its five complementary immunomodulatory transgene payloads and retention of γ 34.5 -- -- Complete and dur...
-- 88,000 square foot state-of-the-art facility will support Oncorus' advancing, multi-product pipeline of intratumorally and intravenously administered viral immunotherapies –
Oncorus to Participate in Fireside Chats at Upcoming Piper Sandler Annual Healthcare Conference and Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announ...
-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the tr...
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to tran...
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc., a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes ...
Oncorus Finalizes $87 Million U.S. IPO Effort
Biotech Oncorus Inc. set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $14 to $16 each.
Oncorus, a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supp... [Read more...]
|IPO Date |
Oct 2, 2020
|Stock Exchange |
|Ticker Symbol |
According to 3 analysts, the average rating for Oncorus stock is "Strong Buy." The 12-month stock price forecast is 38.67, which is an increase of 49.59% from the latest price.